What is the Market's View on Nabriva Therapeutics PLC - ADR (NBRV) Stock's Price and Volume Trends Tuesday?

Tuesday, May 02, 2023 12:57 PM | InvestorsObserver Analysts

Mentioned in this article

What is the Market's View on Nabriva Therapeutics PLC - ADR (NBRV) Stock's Price and Volume Trends Tuesday?

Overall market sentiment has been high on Nabriva Therapeutics PLC - ADR (NBRV) stock lately. NBRV receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Nabriva Therapeutics PLC - ADR has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on NBRV!

See Full NBRV Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With NBRV Stock Today?

Nabriva Therapeutics PLC - ADR (NBRV) stock is flat 0% while the S&P 500 is down -1.46% as of 12:21 PM on Tuesday, May 2. NBRV is flat $0.00 from the previous closing price of $1.60 on volume of 6,128 shares. Over the past year the S&P 500 is lower by -1.16% while NBRV is down -78.84%. NBRV lost -$21.32 per share in the over the last 12 months.

More About Nabriva Therapeutics PLC - ADR

Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of novel antibiotics to treat serious infections. Nabriva Therapeutics has two products: Xenleta (lefamulin), recently approved by the FDA for both Oral and IV use and CONTEPO (fosfomycin) for injection, we submitted an NDA for CONTEPO, a potential first-in-class epoxide antibiotic in the United States for complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP). Our corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and King of Prussia, PA. Nabriva is a commercial-stage biopharmaceutical company with locations in the United States (King of Prussia, PA, San Diego, CA), Austria (Vienna), and Ireland (Dublin), home of our corporate headquarters. Click Here to get the full Stock Report for Nabriva Therapeutics PLC - ADR stock.